# MAY 26 2009

# SUMMArY OF SAFeTY ANd EFFECTIveNESS

Assigned 510(k) Number

The assigned 510(k) number is _ K090257

# Sponsor Name and Address

Siemens Healthcare Diagnostics Inc. 5210 Pacific Concourse Drive   
Los Angeles, CA   
90045-6900   
(310) 645-8200

# Contact

Clare Santulli   
Sr.Regulatory Affairs Specialist   
(914) 524-2701   
(914) 524-3579 fax   
clare.santulli@siemens.com

# Device Name

Trade name: Classification: Classification Names: Regulation Number: Product Code: Catalog Numbers:

IMMULITE® 2000 3gAllergyTM Specific IgE Assay   
Class II   
Radioallergosorbent (RAST) Immunological Test System   
866.5750   
DHB   
L2KUN6 (600 tests)

# Description of Device

IMMULITE® 2000 3gAllergyTM Specific IgE is a solid-phase, two-step, chemiluminescent immunoassay that exploits liquid phase kinetics in a bead format.12 (U.S. Patent No. 4,778,751) It represents a significant advance over conventional methods relying on allergens attached to a solid-phase support, such as a paper disk.

The allergens are covalently bound to a soluble polymer/co-polymer matrix, which in turn is labeled with a ligand. The use of an amino acid co-polymer amplifies the amount of allergen that the matrix can support.

Incubation Cycles: $2 \times 3 0$ minutes.

# Indications for Use

For in vitro diagnostic use with the IMMULITE® 2000 Analyzer — for the quantitative measurement of allergen-specific IgE in human serum, as an aid in the clinical diagnosis of IgE-mediated allergic disorders.

# Establishment Information

IMMULITE® 2000 3gAllergy Specific IgE assay is manufactured by Siemens Healthcare Diagnostics Inc. at the following locations:

Siemens Healthcare Diagnostics Inc. 5210 Pacific Concourse Drive Los Angeles, CA 90045-6900 FDA Establishment #: 3005250747

# Predicate

The purpose of this ${ \mathfrak { s l } } 0 ( { \mathfrak { k } } )$ suiss n ial ell, A E h IMMULITE® 2000 analyzr.

1 Cashew   
2 Pistachio   
3 Walnut   
4 Clam   
5 Oyster   
6 Scallop   
7 Egg

FDA clearance was previously obtained for the assay kit and 196 specific allergens and allergen panels (K013134, K021206, K013135 and K021208).

a Corporation which was acquired by Siemens Medical Solutions Diagnostics in July 2006. Siemens Medical Solutions Diagnostics was renamed Siemens Healthcare Diagnostics Inc. on January 1, 2008.

# Precision

Precision studies were performed in accordance with Clinical Laboratory Standard Institute (CLSI) guidance: Evaluation of Precision Performance of Quantitative Methods; Approved GuidelineSecond Edition. CLSI document EP5-A2 (ISBN 1-56238-542-9). CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004, assaying two aliquots of each test sample in two runs per day on 20 different days. Analysis of variance was used to estimate the within-run and total precision.

Three allergen lots were tested using three positive samples and one negative sample. Intraassay and inter-assay precision for the positive samples were evaluated by calculating the kU/L dose percent coefficients of variation $( \% C V )$ for each positive sample. Non-specific binding (NSB) was monitored by testing the negative control sample.

Repreentative precision claims or ach allergen tested are presented below:

# Allergen Precision Claims\*

<table><tr><td rowspan="2">Sample</td><td rowspan="2">Mean</td><td colspan="2">Within-Run</td><td rowspan="2">Total SD</td><td rowspan="2">CV</td></tr><tr><td>SD</td><td>CV</td></tr><tr><td></td><td>KU/L</td><td>kU/L</td><td>%</td><td>KU/L</td><td>%</td></tr><tr><td>Positive #1</td><td>5.20</td><td>0.198</td><td>Allergen = Cashew, Lot 115</td><td></td><td>5.21</td></tr><tr><td>Positive #2</td><td>9.46</td><td>0.424</td><td>3.81</td><td>0.271 0.563</td><td>5.95</td></tr><tr><td>Positive #3</td><td>4.13</td><td>0.160</td><td>4.48</td><td></td><td>5.84</td></tr><tr><td></td><td></td><td></td><td>3.87</td><td>0.241</td><td></td></tr><tr><td>Positive #1</td><td>14.14</td><td></td><td>Allergen = Pistachio, Lot 114</td><td></td><td></td></tr><tr><td>Positive #2</td><td>4.33</td><td>0.595</td><td>4.21</td><td>0.819</td><td>5.79</td></tr><tr><td>Positive #3</td><td>1.76</td><td>0.211</td><td>4.87</td><td>0.283</td><td>6.54</td></tr><tr><td></td><td></td><td>0.079</td><td>4.49</td><td>0.106</td><td>6.02</td></tr><tr><td></td><td></td><td></td><td>Allergen =Walnut, Lot 118</td><td></td><td></td></tr><tr><td>Positive #1 Positive #2</td><td>5.75</td><td>0.199</td><td>3.46</td><td>0.334</td><td>5.81</td></tr><tr><td>Positive #3</td><td>8.72</td><td>0.286</td><td>3.28</td><td>0.440</td><td>5.05</td></tr><tr><td></td><td>2.33</td><td>0.091</td><td>3.91</td><td>0.143</td><td>6.14</td></tr><tr><td></td><td></td><td></td><td>Allergen = Clam, Lot 116</td><td></td><td></td></tr><tr><td>Positive #1 Positive #2</td><td>1.43</td><td>0.060</td><td>4.20</td><td>0.081</td><td>5.66</td></tr><tr><td>Positive #3</td><td>4.20</td><td>0.159</td><td>3.79</td><td>0.251</td><td>5.98</td></tr><tr><td></td><td>8.23</td><td>0.373</td><td>4.53</td><td>0.535</td><td>6.50</td></tr><tr><td></td><td></td><td>Allergen = Oyster, Lot 117</td><td></td><td></td><td></td></tr><tr><td>Positive #1</td><td>13.18</td><td>0.715</td><td>5.42</td><td>0.915</td><td>6.94</td></tr><tr><td>Positive #2</td><td>0.74</td><td>0.032</td><td>4.32</td><td>0.042</td><td>5.68</td></tr><tr><td>Positive #3</td><td>5.32</td><td>0.242</td><td>4.55</td><td>0.355</td><td>6.67</td></tr><tr><td></td><td></td><td>Allergen = Scallop, Lot 115</td><td></td><td></td><td></td></tr><tr><td>Positive #1</td><td>7.16</td><td>0.345</td><td>4.82</td><td>0.424</td><td>5.92</td></tr><tr><td>Positive #2</td><td>3.67</td><td>0.171</td><td>4.66</td><td>0.222</td><td>6.05</td></tr><tr><td>Positive #3</td><td>1.04</td><td>0.054</td><td>5.19</td><td>0.070</td><td>6.73</td></tr><tr><td></td><td></td><td>Allergen = Egg,</td><td>Lot 116</td><td></td><td></td></tr><tr><td>Positive #1</td><td>10.55</td><td>0.499</td><td>4.73</td><td>0.648</td><td>6.14</td></tr><tr><td>Positive #2</td><td>3.34</td><td>0.119</td><td>3.56</td><td>0.164</td><td>4.91</td></tr><tr><td>Positive #3</td><td>1.99</td><td>0.109</td><td>5.33</td><td>0.130</td><td>6.53</td></tr></table>

\* data are representative of one lot on one instrument

# Linearity

For each allergen, two samples were diluted in 2-fold serial dilutions to 5 levels. The undiluted (neat) and diluted samples were tested with the specific allergen to demonstrate linearity at concentrations within the assay limits. Regression statistics for each allergen comparing observed to expected data are presented below.

Linearity   

<table><tr><td rowspan=1 colspan=1>Allergen</td><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Cashew</td><td rowspan=1 colspan=1>Y= 1.00X + 0.188</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1.004</td><td rowspan=1 colspan=1>0.985-1.022</td><td rowspan=1 colspan=1>0.188</td><td rowspan=1 colspan=1>-0.036-0.412</td></tr><tr><td rowspan=1 colspan=1>Pistachio</td><td rowspan=1 colspan=1>Y= 1.00X - 0.32</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1.003</td><td rowspan=1 colspan=1>0.988-1.018</td><td rowspan=1 colspan=1>-0.322</td><td rowspan=1 colspan=1>-0.109-0.044</td></tr><tr><td rowspan=1 colspan=1>Walnut</td><td rowspan=1 colspan=1>Y= 1.01X - 0.106</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1.005</td><td rowspan=1 colspan=1>0.9921.018</td><td rowspan=1 colspan=1>-0.106</td><td rowspan=1 colspan=1>-.209- -.004</td></tr><tr><td rowspan=1 colspan=1>Clam</td><td rowspan=1 colspan=1>Y= 1.01X + 0.309</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1.006</td><td rowspan=1 colspan=1>0.979-1.034</td><td rowspan=1 colspan=1>0.309</td><td rowspan=1 colspan=1>-0.209-0.827</td></tr><tr><td rowspan=1 colspan=1>Oyster</td><td rowspan=1 colspan=1>Y= 1.01X + 0.425</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1.011</td><td rowspan=1 colspan=1>0.972-1.050</td><td rowspan=1 colspan=1>0.425</td><td rowspan=1 colspan=1>-0.260-1.10</td></tr><tr><td rowspan=1 colspan=1>Scallop</td><td rowspan=1 colspan=1>Y= 1.00X-0.021</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>0.9861.008</td><td rowspan=1 colspan=1>-0.021</td><td rowspan=1 colspan=1>-0.171-0.129</td></tr><tr><td rowspan=1 colspan=1>Egg</td><td rowspan=1 colspan=1>Y= 1.00X + 0.097</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1.001</td><td rowspan=1 colspan=1>0.9891.013</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>-0.035-0.228</td></tr></table>

# Specificity (Inhibition) Studies

Specificity of each allergen was verified through competitive inhibition testing using a single serum sample or pool of sera. A negative sample was used to measure the background response.

To initiate the inhibition experiment, $7 0 \mu \mathrm { L }$ of undiluted and 4 levels of 5-fold serially diluted inhibitor extract were mixed with $2 5 0 \mu \mathrm { L }$ of sample or pool. This mixture was incubated at room temperature $( 1 5 . 2 8 \ ^ { \circ } \mathrm { C } )$ for 1 hour allowing the immunological reaction to occur. Each sample mixture containing the inhibitor extract and the appropriate controls was assayed with 1 lot of each allergen. The percent $( \% )$ inhibition was calculated according to the following formula:

Response  pos.control (ample mpl) ample esponse withinhibitorexc) (Response of pos. control (pos. sample  neg. sample)) X 100

The inhibition study demonstrated that the allergens tested are inhibited by the relevant inhibitor extract in a concentration dependent fashion. Also, the target $\%$ inhibition of $50 \%$ EY was met. These results indicate specificity of the Cashew, Pistachio, Walnut, Clam, Oyster, Scallop and Egg specific allergens. Summary inhibition table is presented below.

<table><tr><td rowspan=1 colspan=2>Cashew</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=2>Pistachio</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=2>Walnut</td></tr><tr><td rowspan=1 colspan=1>InhibitorConcentration(mg/mL)</td><td rowspan=1 colspan=1>%Inhibition</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>InhibitorConcentration(mg/mL)</td><td rowspan=1 colspan=1>%Inhibition</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>InhibitorConcentration(mg/mL)</td><td rowspan=1 colspan=1>%Inhibition</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>98.83</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.00</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98.57</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>96.78</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>92.43</td></tr><tr><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>95.11</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>89.65</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>78.93</td></tr><tr><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>90.27</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>76.60</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>57.63</td></tr><tr><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>82.88</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>71.68</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>48.28</td></tr><tr><td rowspan=1 colspan=2>Clam</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=2>Oyster</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=2>Scallop</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>98.06</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>97.24</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>99.07</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>89.02</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>93.52</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>96.63</td></tr><tr><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>83.96</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>84.85</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>91.14</td></tr><tr><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>80.64</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>68.39</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>80.40</td></tr><tr><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>77.78</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>54.95</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>69.56</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Egg</td></tr><tr><td rowspan=1 colspan=1>InhibitorConcentration(mg/mL)</td><td rowspan=1 colspan=1>%Inhibition</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>77.37</td></tr><tr><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>48.95</td></tr></table>

# Clinical Performance Studies

Clinical performance of Cashew, Pistachio, Walnut, Clam, Oyster, and Scallop allergens was demonstrated by testing samples from non-atopic individuals and samples from atopic patients with case histories of suspected clinical reactions to the specific allergen or allergy group in the IMMULITE® 2000 3gAllergy Specific IgE assay and comparing results to accompanying clinical information.

The clinical performance of the egg allergen was demonstrated in comparison studies between individual egg constituents (egg white and egg yolk) and the whole egg allergen. Egg white and Egg yolk allergens were previously 510K cleared (K013134/A001 and K013134).

Data summary agreement of the IMMULITE® 2000 3gAllergy results to clinical data is presented in the table below.

<table><tr><td rowspan=1 colspan=1>IMMULITE 2000</td><td rowspan=1 colspan=2>Clinical Data</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Clinical</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>868</td><td rowspan=1 colspan=1>987</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>261</td><td rowspan=1 colspan=1>896</td><td rowspan=1 colspan=1>1,157</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>54.4%</td><td rowspan=1 colspan=1>96.9%</td><td rowspan=1 colspan=1>87.3%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>cYanmaGntaYelowb</td><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>Agreement</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Lower Conf</td><td rowspan=1 colspan=1>48%</td><td rowspan=1 colspan=1>96%</td><td rowspan=1 colspan=1>85%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Upper Conf</td><td rowspan=1 colspan=1>60%</td><td rowspan=1 colspan=1>98%</td><td rowspan=1 colspan=1>89%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=6>Allergens included: Egg, Cashew, Clam, Oyster, Pistachio, Scallop, Walnut</td></tr></table>

IMMULITE® 2000 3gAllergy assay results for all allergens compare well with clinical documentation of presence or absence of signs, symptoms and other diagnostic evidence of allergen sensitivity.

# Conclusions for all Studies

Allergens including Cashew, Pistachio, Walnut, Clam, Oyster, Scallop and Egg for use with the IMMULITE® 2000 3gAllergy Specific IgE assay demonstrate acceptable analytical performance including precision, linearity and specificity. IMMULITE® 2000 assay results compare well with clinical documentation of presence or absence of signs, symptoms and other diagnostic evidence of allergen sensitivity. Substantial equivalence was demonstrated to clinical data, supporting the following intended use of the IMMULITE® 2000 3gAllergys Specific IgE assay and the 11 previously listed allergens:

For in vitro diagnostic use with the IMMULITE® 2000 Analyzer — for the quantitative measurement of allergen-specific IgE in human serum, as an aid in the clinical diagnosis of IgE-mediated allergic disorders.

# MAY 2 6 2009

Siemens Healthcare Diagnostics Inc. c/o Ms. Clare Santulli Sr. Regulatory Affairs Specialist 5210 Pacific Concourse Drive Los Angeles. CA 90045-6900

Re: k090257 Trade/Device Name: IMMULITE $\textsuperscript { \textregistered }$ 2000 3gAllergyM specific IgE Assay Regulation Number: 21 CFR $\ S 8 6 6 . 5 7 5 0$ Regulation Name: Radioallergosorbent (RAST) Immunological Test System Regulatory Class: Class II Product Code: DHB Dated: April 20, 2009 Received: April 22, 2009

Dear Ms. Santulli:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice

Page 2 - Ms. Clare Santulli

requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathbf { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. For more information regarding the reporting of adverse events, please go to   
http://www.fda.gov/cdrh/mdr/. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known):

K090257

Device Name: IMMULITE 3gAllergy™M Specific IgE Assay

Indication For Use:

For in vitro diagnostic use with the IMMULITE 2000 Analyzer — for the quantitative measurement of allergen-specific IgE in human serum, as an aid in the clinical diagnosis of IgE-mediated allergic disorders.

CcR  InD Devva  SeyV